- Home
- PLYA vs APLT Comparison
PLYA vs APLT Comparison
Compare PLYA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLYA
- APLT
- Stock Information
- Founded
- PLYA 2006
- APLT 2016
- Country
- PLYA Netherlands
- APLT United States
- Employees
- PLYA N/A
- APLT N/A
- Industry
- PLYA Hotels/Resorts
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- PLYA Consumer Discretionary
- APLT Health Care
- Exchange
- PLYA Nasdaq
- APLT Nasdaq
- Market Cap
- PLYA 1.2B
- APLT 971.6M
- IPO Year
- PLYA N/A
- APLT 2019
- Fundamental
- Price
- PLYA $9.72
- APLT $9.63
- Analyst Decision
- PLYA Strong Buy
- APLT Strong Buy
- Analyst Count
- PLYA 5
- APLT 5
- Target Price
- PLYA $11.40
- APLT $12.50
- AVG Volume (30 Days)
- PLYA 1.2M
- APLT 1.8M
- Earning Date
- PLYA 11-06-2024
- APLT 11-07-2024
- Dividend Yield
- PLYA N/A
- APLT N/A
- EPS Growth
- PLYA 106.66
- APLT N/A
- EPS
- PLYA 0.49
- APLT N/A
- Revenue
- PLYA $949,669,000.00
- APLT N/A
- Revenue This Year
- PLYA N/A
- APLT N/A
- Revenue Next Year
- PLYA $2.21
- APLT $3,169.03
- P/E Ratio
- PLYA $19.85
- APLT N/A
- Revenue Growth
- PLYA 0.71
- APLT N/A
- 52 Week Low
- PLYA $6.95
- APLT $1.79
- 52 Week High
- PLYA $10.13
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- PLYA 69.35
- APLT 58.33
- Support Level
- PLYA $9.25
- APLT $8.51
- Resistance Level
- PLYA $10.13
- APLT $9.86
- Average True Range (ATR)
- PLYA 0.25
- APLT 0.62
- MACD
- PLYA -0.01
- APLT -0.06
- Stochastic Oscillator
- PLYA 73.55
- APLT 52.74
About PLYA Playa Hotels & Resorts N.V.
Playa Hotels & Resorts NV acts as an owner, operator, and developer of all-inclusive resorts in prime beachfront locations in popular vacation destinations in Mexico and the Caribbean. The company's segments are Yucatan Peninsula, Pacific Coast, Dominican Republic, and Jamaica. It generates a majority of its revenue from the Yucatan Peninsula segment. Its brand profile consists of HYATT ZIVA, HYATT ZILARA, Hilton, JEWEL RESORTS, and others.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.